Skip to content

    Laurus Labs

    LAURUSLABS
    Healthcare·25 Jul 2025
    Management Summary

    Laurus Labs delivered a strong Q1 FY26 performance with robust revenue growth of 31% YoY to ₹1,570 crores, driven by healthy CDMO and formulations demand. Profitability saw significant improvement with gross margins at 59.5% and EBITDA margins at 25%. The company is making strategic investments in capacity expansion, including a large fermentation facility in Vizag, while maintaining a healthy debt profile.

    Highlights

    5

    • Total income from operations reached ₹1,570 crores, marking a 31% year-on-year growth.

    • Gross margins expanded to 59.5%, an increase of approximately 500 basis points, driven by better product mix and process improvements.

    • EBITDA margins significantly improved by 10.5 percentage points, closing at 25% (₹389 crores).

    • CDMO business achieved strong growth with sales of ₹493 crores, reflecting robust demand and sustained progress.

    • Net debt to EBITDA ratio improved to 1.8 from 2.3 in the previous quarter, demonstrating healthy financial management.

    Concerns

    3

    • Laurus Bio (large molecule CDMO) reported subdued Q1 sales of ₹29 crores, flat year-on-year, impacted by customer-specific scale-up challenges.

    • Meaningful revenues from crop sciences are not expected until the next financial year (FY27), indicating a slower ramp-up in this segment.

    • Non-ARV API business is not expected to see momentum in the next few quarters, as resources are being prioritized for CDMO projects.

    Key financials

    Single quarter

    08 metrics
    1. 01Revenue₹1,570 Cr+31%YoY
    2. 02Gross Margin59.5%
    3. 03EBITDA₹389 Cr
    4. 04EBITDA Margin25%
    5. 05PAT₹163 Cr

    Segment breakdown

    • CDMO₹493 Cr17.3%
    • Laurus Bio (Large Molecule CDMO)₹29 Cr1.0%
    • Generics₹1,048 Cr36.7%
    • ARV APIs₹363 Cr12.7%
    • ARV Formulations₹284 Cr9.9%
    • Total ARV (API + Formulations)₹640 Cr22.4%
    Donut· Share of Sales

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹265 crores this quarter · ₹5,000 crores (next 5 years) planned

    mostly from internal accruals

    Debt

    Net ₹2,388 crores · 1.8x EBITDA

    Guidance & targets

    7
    CategoryTargetPriority
    Margin
    Gross Margins
    55% to 60%
    		High
    Revenue
    CDMO Contribution to Revenue
    50%
    		Medium
    Revenue
    Crop Sciences Revenue
    meaningful revenues
    		High
    Revenue
    Non-ARV Formulations Growth
    growth
    		High
    Revenue
    ARV Sales
    ₹2,500 crores plus or minus ₹200 crores
    		High
    Debt
    Net Debt to EBITDA
    2 to 2.5
    		High
    Capacity
    Vizag Fermentation Facility Phase 1
    online
    		High

    CDMO Gross Margin

    coming quarters
    Current59.5% (overall gross margin)
    Target55-60%

    Why it matters

    Sustainability of improved profitability, driven by CDMO segment, is key to overall margin expansion.

    Now you can say as the contribution from CDMO business increases, we expect the gross margins will remain between 55% to 60%. That's what we expect in the coming quarters.

    How to verify

    key_financials.metrics[label='Gross Margin']

    Risks & concerns

    3
    RiskSeverity

    Subdued Laurus Bio Sales due to Customer Challenges

    Laurus Bio's Q1 sales were flat year-on-year at ₹29 crores due to customer-specific scale-up challenges, though management states the bottleneck is resolved. — Management acknowledged

    medium

    Impact of 'Make in America' on Outsourcing/CDMO

    Concerns raised about US Big Pharma investing domestically. Management believes core chemistry will remain outsourced, but cell/gene therapy and finishing steps might move, while intermediate demand remains constant or increasing. — Analyst acknowledged

    medium

    Significant Price Drops in ARV Segment

    Management cited 'significant price drops in ARVs' as a reason for maintaining conservative full-year guidance for the ARV segment, despite Q1 growth. — Management acknowledged

    medium

    Q&A highlights

    8

    “Now you can say as the contribution from CDMO business increases, we expect the gross margins will remain between 55% to 60%. That's what we expect in the coming quarters.”

    Addresses investor concerns about the sustainability of the significantly improved gross margins and links it directly to the growing CDMO segment.

    asked by Bharat Sheth

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Performance Overview

    Laurus Labs commenced FY26 with healthy progress, reporting total income from operations of ₹1,570 crores, a 31% year-on-year increase. Gross margins expanded significantly to 59.5%, an improvement of approximately 500 basis points, attributed to a better product mix and process efficiencies. EBITDA for the quarter stood at ₹389 crores, with EBITDA margins reaching 25%, a 10.5 percentage point expansion. Profit after tax was ₹163 crores, and ROCE was 13%.

    02

    CDMO Business Highlights

    The CDMO division demonstrated strong performance, registering sales of ₹493 crores in Q1 FY26, driven by sustained demand for high-value integrated offerings. The company noted healthy pipeline momentum across clinical and commercial phases, with over 110 active projects. Laurus Bio, the large molecule CDMO division, however, reported subdued sales of ₹29 crores, remaining flat year-on-year due to customer-specific scale-up challenges, which are now resolved.

    03

    Generics Business Performance

    The Generics division achieved sales of ₹1,048 crores, marking a 12% growth, primarily supported by volume expansion in both ARV and developed markets. ARV APIs contributed ₹363 crores, and ARV formulations added ₹284 crores, totaling ₹640 crores for the ARV segment. The company continues to focus on rebalancing R&D and manufacturing resources to enhance its product pipeline and meet delivery commitments, with non-ARV formulations expected to grow from Q4 onwards.

    04

    Strategic Capacity Expansion and Investments

    Laurus Labs announced three major capacity expansions: a microbial fermentation Phase 1 greenfield project at Vizag (400 kiloliter capacity, expected online by end of 2026), a gene therapy and antibody-drug conjugate GMP facility in Hyderabad (6,000 sq m), and a finished formulation facility in Hyderabad under a joint venture. These investments are part of a larger ₹5,000 crores capex plan over the next 5 years, primarily in Vizag, aimed at strengthening manufacturing capabilities and driving future growth.

    05

    Financial Health and Capital Allocation

    The company's net debt stood at ₹2,388 crores, with the net debt to EBITDA ratio improving to 1.8 from 2.3 in the previous quarter. Management reiterated its commitment to maintaining a healthy financial profile, aiming to keep debt by EBITDA at a maximum of 2 to 2.5. The ₹5,000 crores capex plan is expected to be largely funded through internal accruals, ensuring that the company's net debt does not exceed 50% of its annual revenue.

    06

    R&D and Quality Initiatives

    R&D spending for Q1 FY26 was ₹68 crores, representing 4.3% of sales, an increase of 6% year-on-year. This expenditure aligns with the full-year target and supports portfolio investments, including cell and gene therapy, and sustainable technologies. The company successfully passed 39 quality audits by multiple regulatory bodies and key customers in Q1 without any critical findings, underscoring its commitment to quality standards.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.